Abstract library

267 results for "17AAG".
#122 Molecular genetic findings in gastric carcinoid suggest possible neurofibromin/Ras pathway involvement in carcinoid pathogenesis
Introduction: The molecular pathogenesis of gastrointestinal carcinoid tumours is poorly understood. We have been undertaking molecular genetic investigations of a young woman with neurofibromatosis type 1 (NF1) in whom a gastric carcinoid tumor was detected following an episode of gastrointestinal bleeding. She was otherwise relatively mildly affected by NF1. In NF1, gastric carcinoids have been found previously only in patients with other predisposing factors, which were absent in this patient.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Edward S Tobias
#508 Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray
Introduction: Molecular mechanisms driving well-differentiated midgut carcinoid (MGC) tumors are not well-established. To pursue higher resolution tumor diagnostics, we studied a panel of markers for their expression in MGC, including: serotonin, FGF2, b-catenin, and E-cadherin, in primary, lymph node, and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
Authors: Liu E, Mikhitarian K, Revetta F, Shi C, ...
#608 Is Octreotide Benefitial in Patients with Metastatic Gastroenteropancreatic (GEP) and Hepatobiliary Neuroendocrine Carcinoma (NEC)?
Introduction: Neuroendocrine carcinomas (NECs) of the gastroenteropancreatic (GEP) and hepatobiliary (HB) tract are rare and a heterogenous group of malignancies. Octreotide showed the anti-tumor activity in well-differentiated metastatic midgut neuroendocrine tumors (NETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Seung Kim
Authors: Kim S, ...
Keywords: NEC, octreotide, GEP, HB
#1143 Ectopic Cushing’s Syndrome (ECS) in Patients with Neuroendocrine Neoplasms
Introduction: Ectopic Cushing syndrome (ECS) has been described in patients with neuroendocrine neoplasms (NENs)
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Krystallenia Alexandraki
Keywords: ECS
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST
#1285 Gastrointestinal Neuroendocrine Tumors of Unknown Primary Site: Report from a Series at a Single Institute
Introduction: Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic behavior, histologic appearance and clinical outcome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: dr Sara Massironi
#1402 Merkel Cell Carcinoma of Lymph Node Without Skin Primary Can - and Should - Be Distinguished from Others Metastatic Neuroendocrine Carcinoma
Introduction: Merkel cell carcinoma of lymph node without primary tumour (MCCNWP) is a rare tumour which can be misinterpreted as lymph node metastasis (LNM) from a high-grade neuroendocrine carcinoma (NEC) on histological examination. However, this distinction is crucial for therapeutic management.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Prof. Serge Guyetant
#2084 A Comparison of Diagnostic and Management Pathways for Patients with Lung Neuroendocrine Tumors in ENETS Centres of Excellence vs Non-Accredited Centres in the UK: Results from the National Lung NET Pathway Project (‘LEAP’)
Introduction: The ENETS network of accredited NET Centres of Excellence (CoE) across Europe was established to standardise and improve NET management.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Stuart Ferguson
Authors: Talbot D, Ferguson S, Mansoor W, ...
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein